EPIRUS Biopharmaceuticals expands biosimilar pipeline and capabilities with acquisition

EPIRUS Biopharmaceuticals, Inc. has announced an agreement for the acquisition of Bioceros Holding B.V enabling EPIRUS to expand its biosimilar pipeline and vertically integrate product development capabilities.

From the Bioceros platform, EPIRUS will expand its pipeline with the addition of three preclinical product candidates: BOW080, a proposed biosimilar to eculizumab; BOW090, a proposed biosimilar to ustekinumab, and BOW100, a proposed biosimilar to goluimnab.

These three new pipeline assets represent a global growth opportunity for EPIRUS in targeting biologics with esteimated 2020 peak sales of $12 billion. The platform also enables future pipeline growth opportunities for the company.

“Building a focussed, sustainable and profitable biosimilar business requires capabilities for efficient pipeline growth. With this in mind, we are excited to welcome Bioceros and their world-class capabilities and expertise,” says Amit Munshi (pictured) President and CEO of EPIRUS. “Together, we will continue working to improve patient access to important, cost-effective medicines worldwide. Our combined biosimilar pipeline targets biologics with sales of $29 billion, which we estimate to be a biosimilar market opportunity of more than $9 billion.”

Bram Bout, Ph.D., CEO and Chairman of the management board, Bioceros, adds: “Having worked with Epirus as a partner over the last several years, we believe stringing in the Company’s vision and their ability to execute. With our proven track record, our team brings substantial cell line and process development experience, representing a strong asset for Epirus.”

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focussed on the development of biosimilar monoclonal antibodies (mAbs) and generation of GMP-ready vell lines. Over the past decade, the company has developed numerous biosimilar cell lines from its proprietary, well-characterised CHO platform. Its staff of scientists, fully-equipped labs and bioreactor capabilities have been designed for the development of mAbs and protein therapeutics, with a focus of biosimilars.

Based on materials supplied by EPIRUS Biopharmaceuticals.


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients...

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Related news

CDMOs team up to simplify processes, optimise time-to-market

CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development...

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...